Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2019-09-29 Earnings Release
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
Earnings Release Classification · 99% confidence The document is dated September 29, 2019, and announces positive overall survival results from the MONALEESA-3 clinical trial for the drug Kisqali (ribociclib). It details efficacy, safety data, and mentions that the full data will be presented at the ESMO Congress. This structure—a press release announcing key clinical trial results and financial/product updates—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on announcing new results rather than being a comprehensive periodic report (like 10-K or IR) or a transcript (CT), 'ER' (Earnings Release) is the most appropriate fit, as pharmaceutical companies often issue press releases for major trial data alongside or instead of traditional earnings reports to communicate performance drivers. It is not a formal regulatory filing like a 10-K or IR, nor is it a short announcement about a report (RPA/RNS). Q3 2019
2019-09-29 English
FORM 6-K
Regulatory Filings
2019-09-17 English
Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Legal Proceedings Report Classification · 99% confidence The document is dated September 17, 2019, and announces positive new data from the PREVENT Phase III trial for Cosentyx in treating nr-axSpA. It details study endpoints, patient populations, and includes forward-looking statements and references to regulatory submissions (EMA submission mentioned). This format—a formal announcement of clinical trial results and regulatory progress, typically issued via press release—aligns best with an Earnings Release (ER) if it were quarterly results, but since it is a specific clinical/drug development update, it functions as a key corporate announcement. Given the options, this is a press release announcing significant corporate/product news, which often overlaps with the function of an Earnings Release (ER) in terms of immediate market impact, or could be considered a Regulatory Filing (RNS) if it were a mandatory filing. However, the structure strongly suggests a press release detailing recent operational/clinical achievements, which is often categorized as an Earnings Release (ER) when it contains material financial implications, or sometimes as a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a formal announcement of results, ER is the closest fit for a major, time-sensitive corporate update, even if not strictly quarterly earnings. Given the context of major drug trial success, it is a high-impact announcement.
2019-09-17 English
FORM 6-K
Regulatory Filings
2019-08-30 English
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
Regulatory Filings Classification · 95% confidence The document is a press release from Novartis announcing positive Phase III clinical trial results for their drug ofatumumab. It details the study endpoints, methodology, and future regulatory plans. This type of announcement, which focuses on clinical trial outcomes and product development updates rather than financial earnings or annual reports, is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement regarding company activities.
2019-08-30 English
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
Regulatory Filings Classification · 95% confidence The document is a press release from Novartis announcing positive Phase III clinical trial results for their drug ofatumumab. It details the study endpoints, methodology, and future regulatory plans. It does not contain full financial statements, nor is it a regulatory filing or a report publication announcement. It falls under the category of general regulatory announcements/corporate news, which is best classified as RNS (Regulatory Filings) as it is a standard corporate press release regarding clinical trial outcomes.
2019-08-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.